Influence of Neoadjuvant Chemotherapy on the Expression of Drug Resistance Genes in Breast Carcinoma

Linbo Wang
2006-01-01
Abstract:Objective To investigate the influence of different neoadjuvant chemotherapeutic regimens on drug resistance phenotype of breast carcinoma. Methods Immunohistochemical study was carried out on pre-treatment biopsy specimens and surgical specimens from the individual breast carcinoma patients to detect the expression of three drug resistance genes: multidrug resistance associated protein ( MRP1 ) , glutathione-S-transferase pi ( GST-π ) and topoinsomerase Ⅱ ( TOPO- Ⅱ ) , under three chemotherapeutic regimens (VCF, CEF and TEC). Results VCF regimen was the most powerful. In 22 GST-π negative cases, 8 cases turned to positive (P 0. 05). Prechemotherapy positive TOPO- Ⅱ expression turned to negative in 6 cases (P 0. 05 ). In CEF regimen group ( 13 cases) , positive TOPO- Ⅱ expression turned to negative in 4 cases. Negative GST-π expression turned to positive in 4 cases. TEC regimen had the least influence on drug resistance phenotype, with MRP1 expression turning to negative in 3 cases. Conclusion Different neoadjuvant chemotherapy regimen for breast carcinoma alters the expression of drug resistance genes with varied extent.
What problem does this paper attempt to address?